NasdaqCM - Nasdaq Real Time Price USD

Tiziana Life Sciences Ltd (TLSA)

1.1100

-0.0200

(-1.79%)

As of 10:01:55 AM EDT. Market Open.

Tiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab in Phase 2 Multiple Sclerosis Clinical Trial

NEW YORK, April 02, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced dosing has commenced at Johns Hopkins University (JHU) Autoimmunity Center of Excellence, the third clinical site in its Phase 2 trial evaluating intranasal foralumab for the treatment of

GlobeNewswire 20 days ago

TLSA
-1.79%
Tiziana Life Sciences begins dosing in trial of therapy for multiple sclerosis

The trial aims to evaluate the antibody’s efficacy in treating non-active secondary progressive multiple sclerosis.

Clinical Trials Arena 27 days ago

TLSA
-1.79%
Tiziana Life Sciences Announces Yale University Commences Intranasal Foralumab Dosing in Phase 2 Multiple Sclerosis Trial

NEW YORK, March 25, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced dosing of new patients at Yale MS Center which is participating in our multicenter Phase 2 clinical trial evaluating intranasal foralumab for non-active Secondary Progressive Multiple Scl

GlobeNewswire 28 days ago

TLSA
-1.79%
Tiziana Life Sciences to Present at the 37th Annual Roth Conference

NEW YORK, March 17, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that the CEO of Tiziana Life Sciences, Ivor Elrifi, will be presenting during a fireside chat at the 37th Annual ROTH Conference and host 1x1 investor meetings. The Conference is being he

GlobeNewswire last month

TLSA
-1.79%
Tiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price Rule

NEW YORK, March 14, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that it has received a notification from the Nasdaq Stock Market LLC (“Nasdaq”) Listing Qualifications Department informing the Company that it has regained compliance with the Nasdaq lis

GlobeNewswire last month

TLSA
-1.79%
Oramed Pharmaceuticals And 2 Other Penny Stocks With Promising Potential

As the United States stock market grapples with volatility, driven by concerns about economic health and shifting investor sentiment, opportunities in lesser-known areas like penny stocks are gaining attention. While the term 'penny stocks' might seem outdated, these investments often represent smaller or newer companies that can offer growth potential at lower price points. When backed by strong financials and sound fundamentals, they provide investors a chance to uncover hidden value amidst...

Simply Wall St. last month

TLSA
-1.79%
ORMP

AVIR
Sector Update: Health Care Stocks Lower Late Afternoon

Health care stocks declined late Tuesday afternoon, with the NYSE Health Care Index down 0.5% and th

PREMIUM
MT Newswires last month

UNH

WBA

TLSA
-1.79%
Tiziana Life Sciences Files Investigational New Drug Application with FDA for ALS Phase 2 Clinical Trial

NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced the submission of its Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for a phase 2 clinical trial in ALS. This pivotal step marks a significant

GlobeNewswire last month

TLSA
-1.79%
Why Tiziana Life Sciences Ltd (TLSA) is Skyrocketing So Far in 2025

We recently published an article titled Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025. In this article, we are going to take a look at where Tiziana Life Sciences Ltd (NASDAQ:TLSA) stands against the other biotech stocks. No matter the market environment, you’ll always find entertainment in the biotech space. There will always […]

Insider Monkey last month

TLSA
-1.79%
Tiziana Life Sciences Announces Groundbreaking Study Published in Nature Neuroscience Demonstrating Positive Results for Nasal Anti-CD3 Therapy in Traumatic Brain Injury

Traumatic brain injury is a leading cause of death and disabilityCurrently, there is no treatment to prevent the long-term effects of traumatic brain injuryFindings could translate into treating intracerebral hemorrhage or stroke NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti

GlobeNewswire last month

TLSA
-1.79%
Tiziana Life Sciences Announces Long Covid Study to Complete in Second Quarter

NEW YORK, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that a nasal anti-CD3 (foralumab) preclinical study is nearing completion, and that foralumab could offer a novel and effective treatment for long COVID. This innovative approach works by

GlobeNewswire last month

TLSA
-1.79%
Tiziana Life Sciences Announces Agreement for Product Development Services with Renaissance Lakewood, LLC

NEW YORK, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced a product development services agreement with Renaissance Lakewood LLC (“Renaissance”), a leading Contract Development and Manufacturing Organization (CDMO) focused on nasal drug delivery.

GlobeNewswire last month

TLSA
-1.79%
Tiziana Life Sciences Announces Dosing of Additional Patients in Multiple Sclerosis Expanded Access Program

NEW YORK, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced the dosing of an additional four patients in its Intermediate Size Patient Population Expanded Access (ISPPEA) for patients with non-active secondary progressive multiple sclerosis (na-SPM

GlobeNewswire 2 months ago

TLSA
-1.79%
3 Promising US Penny Stocks With Market Caps Over $20M

As the U.S. stock market navigates the complexities of new tariffs and Federal Reserve policies, investors are keenly observing how these factors impact various indices. Amidst this backdrop, penny stocks—often representing smaller or emerging companies—continue to capture attention due to their potential for growth at lower price points. Despite their vintage name, these stocks can offer significant value when backed by strong financials and a clear growth strategy. In this article, we...

Simply Wall St. 2 months ago

TLSA
-1.79%
SOPH

CPSH
Tiziana Life Sciences Announces TV Interview with First Patient Dosed with Moderate Alzheimer’s Disease

Joe and his Wife, Karen, shared their journey and shed light on the hope that innovative therapies like Foralumab offer for individuals battling moderate Alzheimer’s, a condition that currently has no cure and limited treatment options. NEW YORK, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully huma

GlobeNewswire 2 months ago

TLSA
-1.79%
Tiziana Life Sciences Announces Positive Results in Treating Spinal Cord Injury With Nasal Anti-CD3

NEW YORK, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced results from studies using a nasal anti-CD3 monoclonal antibody in traumatic spinal cord injury (SCI). Spinal cord injury is a devastating global health issue with profound implications fo

GlobeNewswire 2 months ago

TLSA
-1.79%
Tiziana Life Sciences not to engage in capital raising activities for the immediate future

NEW YORK, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announces its intention not to engage in a capital raising activities for the immediate future. Following on from its news yesterday of the discovery of new immune biomarkers in patients with non-ac

GlobeNewswire 2 months ago

TLSA
-1.79%
Tiziana Life Sciences Announces Discovery of New Immune Biomarkers in Multiple Sclerosis Patients Treated with Nasal Foralumab

NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced the discovery of new immune biomarkers in patients with non-active secondary progressive multiple sclerosis (na-SPMS) treated with nasal foralumab. We believe these findings contribute sub

GlobeNewswire 2 months ago

TLSA
-1.79%
3 Penny Stocks In US With Market Caps Below $300M

As the U.S. stock market faces a challenging period with major indexes declining for the second consecutive week, investors are navigating an environment shaped by rising Treasury yields and robust economic data. Amidst this backdrop, penny stocks—despite their somewhat outdated moniker—remain a relevant area of interest for those seeking unique investment opportunities. These smaller or newer companies can offer growth potential at lower price points, especially when they possess strong...

Simply Wall St. 3 months ago

GNTA

TLSA
-1.79%
PERF
Tiziana Announces Reduction of Side Effects Commonly Seen with Discontinuation of GLP-1 Agonists with Nasal Anti-CD3

NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced findings on the prolonged benefits of its nasal anti-CD3 monoclonal antibody in sustaining tissue homeostasis and mitigating the side effects associated with GLP-1 agonists discontinuation

GlobeNewswire 3 months ago

TLSA
-1.79%

Performance Overview

Return	TLSA	S&P 500 (^GSPC)
YTD	+58.57%	-10.89%
1-Year	+48.00%	+4.60%
3-Year	+11.00%	+22.69%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Tiziana Life Sciences Ltd (TLSA)

Tiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab in Phase 2 Multiple Sclerosis Clinical Trial

Tiziana Life Sciences begins dosing in trial of therapy for multiple sclerosis

Tiziana Life Sciences Announces Yale University Commences Intranasal Foralumab Dosing in Phase 2 Multiple Sclerosis Trial

Tiziana Life Sciences to Present at the 37th Annual Roth Conference

Tiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price Rule

Oramed Pharmaceuticals And 2 Other Penny Stocks With Promising Potential

Sector Update: Health Care Stocks Lower Late Afternoon

Tiziana Life Sciences Files Investigational New Drug Application with FDA for ALS Phase 2 Clinical Trial

Why Tiziana Life Sciences Ltd (TLSA) is Skyrocketing So Far in 2025

Tiziana Life Sciences Announces Groundbreaking Study Published in Nature Neuroscience Demonstrating Positive Results for Nasal Anti-CD3 Therapy in Traumatic Brain Injury

Tiziana Life Sciences Announces Long Covid Study to Complete in Second Quarter

Tiziana Life Sciences Announces Agreement for Product Development Services with Renaissance Lakewood, LLC

Tiziana Life Sciences Announces Dosing of Additional Patients in Multiple Sclerosis Expanded Access Program

3 Promising US Penny Stocks With Market Caps Over $20M

Tiziana Life Sciences Announces TV Interview with First Patient Dosed with Moderate Alzheimer’s Disease

Tiziana Life Sciences Announces Positive Results in Treating Spinal Cord Injury With Nasal Anti-CD3

Tiziana Life Sciences not to engage in capital raising activities for the immediate future

Tiziana Life Sciences Announces Discovery of New Immune Biomarkers in Multiple Sclerosis Patients Treated with Nasal Foralumab

3 Penny Stocks In US With Market Caps Below $300M

Tiziana Announces Reduction of Side Effects Commonly Seen with Discontinuation of GLP-1 Agonists with Nasal Anti-CD3

Performance Overview